Charles River Laboratories Intl. Inc (NYSE:CRL) Director Robert J. Bertolini sold 3,440 shares of the business’s stock in a transaction that occurred on Tuesday, December 4th. The shares were sold at an average price of $133.77, for a total value of $460,168.80. Following the completion of the transaction, the director now directly owns 29,876 shares of the company’s stock, valued at $3,996,512.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Shares of Charles River Laboratories Intl. stock traded down $1.03 on Thursday, reaching $132.59. The company’s stock had a trading volume of 1 shares, compared to its average volume of 397,988. The stock has a market capitalization of $6.43 billion, a PE ratio of 24.81, a price-to-earnings-growth ratio of 1.88 and a beta of 0.74. Charles River Laboratories Intl. Inc has a 52-week low of $96.70 and a 52-week high of $139.72. The company has a debt-to-equity ratio of 1.32, a current ratio of 1.55 and a quick ratio of 1.32.

Charles River Laboratories Intl. (NYSE:CRL) last posted its quarterly earnings data on Wednesday, November 7th. The medical research company reported $1.53 EPS for the quarter, beating the Zacks’ consensus estimate of $1.38 by $0.15. Charles River Laboratories Intl. had a return on equity of 25.08% and a net margin of 6.39%. The business had revenue of $585.30 million during the quarter, compared to analysts’ expectations of $567.58 million. During the same period in the previous year, the business earned $1.30 earnings per share. The business’s revenue was up 26.1% compared to the same quarter last year. On average, equities research analysts anticipate that Charles River Laboratories Intl. Inc will post 5.92 EPS for the current fiscal year.

Institutional investors and hedge funds have recently modified their holdings of the stock. Rhumbline Advisers increased its position in shares of Charles River Laboratories Intl. by 4.7% during the second quarter. Rhumbline Advisers now owns 106,963 shares of the medical research company’s stock worth $12,008,000 after purchasing an additional 4,842 shares in the last quarter. Mackay Shields LLC increased its position in shares of Charles River Laboratories Intl. by 272.4% during the second quarter. Mackay Shields LLC now owns 46,182 shares of the medical research company’s stock worth $5,184,000 after purchasing an additional 33,781 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new stake in shares of Charles River Laboratories Intl. during the second quarter worth approximately $460,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Charles River Laboratories Intl. during the second quarter worth approximately $212,000. Finally, Cadence Capital Management LLC increased its position in shares of Charles River Laboratories Intl. by 7.1% during the third quarter. Cadence Capital Management LLC now owns 13,142 shares of the medical research company’s stock worth $1,768,000 after purchasing an additional 873 shares in the last quarter. Hedge funds and other institutional investors own 96.20% of the company’s stock.

A number of research analysts have issued reports on the company. Raymond James reissued a “buy” rating and issued a $150.00 price target on shares of Charles River Laboratories Intl. in a report on Tuesday. ValuEngine upgraded Charles River Laboratories Intl. from a “hold” rating to a “buy” rating in a research report on Tuesday, September 11th. Jefferies Financial Group boosted their price objective on Charles River Laboratories Intl. from $140.00 to $145.00 and gave the company a “buy” rating in a research report on Thursday, August 9th. SunTrust Banks boosted their price objective on Charles River Laboratories Intl. to $135.00 and gave the company a “buy” rating in a research report on Thursday, August 9th. Finally, Morgan Stanley boosted their price objective on Charles River Laboratories Intl. from $112.00 to $136.00 and gave the company an “equal weight” rating in a research report on Monday. Eight equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Charles River Laboratories Intl. currently has a consensus rating of “Buy” and an average target price of $132.06.

WARNING: This article was first posted by Watch List News and is the property of of Watch List News. If you are viewing this article on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this article can be accessed at https://www.watchlistnews.com/charles-river-laboratories-intl-inc-crl-director-robert-j-bertolini-sells-3440-shares/2664512.html.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Featured Article: How to Use a Moving Average for TradingĀ 

Insider Buying and Selling by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.